summary: This preliminary study investigated the safety and efficacy of stem cell transplantation in people with relapsing-remitting MS who did not respond to beta-interferon. It was found that it stopped progression and improved disability. However, some important side effects were reported. Further and larger studies are needed to confirm these results.

authors: Burt RK, Loh Y, Cohen B, Stefosky D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH

source: Lancet Neurol. 2009 Jan 29. [Epub ahead of print]

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: